ANTH-301

ANTH-301 is a drug candidate initially developed by Anthos Therapeutics, which was subsequently acquired by Novartis. The available information presents conflicting descriptions regarding its nature and mechanism of action. It is described as both a gene therapy candidate for cardiovascular disease, currently in Phase 1/2 clinical development, and a selective PDE9 inhibitor for cardiovascular diseases, in Phase 2 development. Novartis's acquisition of Anthos Therapeutics, valued at $925 million upfront and up to $2.2 billion in potential milestones, was intended to expand its cardiovascular pipeline with ANTH-301.